Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boulder/denver blog main
boulder/denver top stories
deals
8
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
8
×
new york blog main
8
×
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
startups
cancer
biogen
cancer immunotherapy
eli lilly
medicare
pfizer
abbvie
alzheimer's disease
amgen
crispr
What
bio
roundup
8
×
drug
acquisitions
ceo
alzheimer’s
biggest
companies
daniel
gene
gilead
life
millions
moves
new
o’day
patients
pharmaceutical
price
science
sciences
talk
terms
typically
albert
announced
approval
bails
becker
billions
biogen’s
biopharmaceutical
bourla
brand
bridgebio
build
buy
capital
car
collabs
Language
unset
unknown
Current search:
roundup
×
novartis
×
deals
×
" national top stories "
×
" new york blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel